About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker PHAT · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Oct 13, 2026A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 We…
NCT06851559 · Eosinophilic Esophagitis
Vonoprazan, Placebo
PHAT
Phathom Pharmaceuticals, Inc.
Phase 2Active, not recruiting95Sep 11, 2026Registry ↗
Oct 7, 2026A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of E…
NCT07752407 · Symptomatic Non-erosive Gastroesophageal Reflux Disease
Vonoprazan, Placebo
PHAT
Phathom Pharmaceuticals, Inc.
Phase 3Recruiting500Oct 20, 2027Registry ↗
Sep 18, 2026A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
NCT06660342 · Erosive Esophagitis, Heartburn
Vonoprazan
PHAT
Phathom Pharmaceuticals, Inc.
—Recruiting728Sep 2034Registry ↗
Dec 19, 2025A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without W…
NCT06831344 · Healthy Volunteers
Vonoprazan ODT-1 or ODT-2 without Water, Vonoprazan ODT-1 o…
PHAT
Phathom Pharmaceuticals, Inc.
Phase 1Completed25Apr 5, 2025Registry ↗
Apr 23, 2025A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents…
NCT05343364 · Gastroesophageal Reflux
Vonoprazan
PHAT
Phathom Pharmaceuticals, Inc.
Phase 1Completed24May 30, 2023Registry ↗
Mar 25, 2025A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving V…
NCT06391177 · Erosive Esophagitis, Heartburn
Vonoprazan
PHAT
Phathom Pharmaceuticals, Inc.
Phase 1Completed15Sep 13, 2024Registry ↗
Dec 19, 2024A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease
NCT06106022 · Gastroesophageal Reflux Disease
Vonoprazan
PHAT
Phathom Pharmaceuticals, Inc.
Phase 1Completed22Apr 16, 2024Registry ↗
Mar 29, 2024A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauc…
NCT05366738 · Healthy Volunteers
Vonoprazan, Vonoprazan
PHAT
Phathom Pharmaceuticals, Inc.
Phase 1Completed27Jul 1, 2022Registry ↗
Dec 29, 2023A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartbu…
NCT05195528 · Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
Vonoprazan, Placebo
PHAT
Phathom Pharmaceuticals, Inc.
Phase 3Completed776Nov 21, 2022Registry ↗
Mar 31, 2023Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole…
NCT04729101 · Healthy Participants
Vonoprazan, Lansoprazole
PHAT
Phathom Pharmaceuticals, Inc.
Phase 1Completed44Jun 12, 2021Registry ↗
Mar 17, 2023Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants
NCT04545944 · Healthy Volunteers
Vonoprazan, Midazolam
PHAT
Phathom Pharmaceuticals, Inc.
Phase 1Completed20Nov 13, 2020Registry ↗
Jan 4, 2023A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With…
NCT04799158 · Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
Vonoprazan, Placebo
PHAT
Phathom Pharmaceuticals, Inc.
Phase 2Completed458Dec 16, 2021Registry ↗
Jul 29, 2022Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis
NCT04124926 · Erosive Esophagitis
Vonoprazan, Lansoprazole
PHAT
Phathom Pharmaceuticals, Inc.
Phase 3Completed1,027Jul 29, 2021Registry ↗
Apr 5, 2022Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori…
NCT04167670 · Helicobacter Pylori Infection
Vonoprazan, Amoxicillin
PHAT
Phathom Pharmaceuticals, Inc.
Phase 3Completed1,046Mar 10, 2021Registry ↗
Mar 2, 2022Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants
NCT04558216 · Healthy Participants
Vonoprazan, Rifampin
PHAT
Phathom Pharmaceuticals, Inc.
Phase 1Withdrawn0Feb 7, 2021Registry ↗

15 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:50 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances